MARKET

COGT

COGT

Cogent Biosciences Inc
NASDAQ
39.53
-0.37
-0.93%
After Hours: 39.53 0 0.00% 16:10 01/22 EST
OPEN
40.00
PREV CLOSE
39.90
HIGH
40.39
LOW
39.29
VOLUME
5.30M
TURNOVER
--
52 WEEK HIGH
43.73
52 WEEK LOW
3.720
MARKET CAP
6.07B
P/E (TTM)
-22.3776
1D
5D
1M
3M
1Y
5Y
1D
Fairmount Funds Management LLC Reports Disposal of Cogent Biosciences Inc. Common Shares
Reuters · 31m ago
A Look At Cogent Biosciences (COGT) Valuation After FDA Accepts Bezuclastinib NDA Under RTOR Program
Simply Wall St · 1d ago
FDA Accepts NDA for Cogent Biosciences' Bezuclastinib Combination in GIST Under RTOR Program
Reuters · 2d ago
Cogent to initiate New Drug Application submission for bezuclastinib
TipRanks · 2d ago
COGENT BIOSCIENCES INC - TO INITIATE RTOR PROCESS, COMPLETION OF PEAK NDA SUBMISSION BY APRIL 2026
Reuters · 2d ago
COGENT BIOSCIENCES TO INITIATE NEW DRUG APPLICATION (NDA) SUBMISSION FOR BEZUCLASTINIB UNDER REAL-TIME ONCOLOGY REVIEW (RTOR) 
Reuters · 2d ago
Weekly Report: what happened at COGT last week (0112-0116)?
Weekly Report · 3d ago
Why Cogent Biosciences (COGT) Is Up 10.3% After Mapping Bezuclastinib’s Multi-Indication NDA Strategy
Simply Wall St · 6d ago
More
About COGT
Cogent Biosciences, Inc. is a biotechnology company. The Company is focused on developing precision therapies for genetically defined diseases. The Company’s clinical program, bezuclastinib, is a selective tyrosine kinase inhibitor that is designed to potently inhibit the KIT D816V mutation as well as other mutations in KIT exon 17. KIT D816V is responsible for driving systemic mastocytosis, a serious disease caused by unchecked proliferation of mast cells. In addition to bezuclastinib, the Company is developing a portfolio of novel targeted therapies to help patients fighting serious, genetically driven diseases initially targeting mutations in FGFR2, ErbB2 and PI3Kα. SUMMIT is its randomized, global, multicenter, double-blind, placebo-controlled, multi-part Phase II clinical trial for patients with Non-AdvSM. APEX is an open-label, global, multicenter study evaluating the safety, efficacy, pharmacokinetic, and pharmacodynamic profiles of bezuclastinib.

Webull offers Cogent Biosciences Inc stock information, including NASDAQ: COGT real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, COGT stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading COGT stock methods without spending real money on the virtual paper trading platform.